Company profile: Previse
1.1 - Company Overview
Company description
- Provider of life sciences diagnostics focused on developing and commercializing diagnostic tests for cancer prevention and early detection, with specialization across diagnostics, medical devices, medicine, and Medtech.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Previse
Foundation Medicine
HQ: United States
Website
- Description: Provider of molecular information and clinical diagnostic tests for personalized cancer care, including FoundationOne CDx tissue-based comprehensive genomic profiling, FoundationOne Liquid CDx blood-based ctDNA profiling, FoundationOne Heme for hematologic malignancies, FoundationOne RNA fusion detection in solid tumors, the FoundationCore cancer genomic database, and Molecular Tumor Boards.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foundation Medicine company profile →
Dice Therapeutics
HQ: United States
Website
- Description: Provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral α4β7 for IBD, oral αVβ1/αVβ6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dice Therapeutics company profile →
CatalYm
HQ: Germany
Website
- Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CatalYm company profile →
Theolytics
HQ: United Kingdom
Website
- Description: Provider of next-generation viral therapies, leveraging phenotypic screening platforms to discover targeted oncolytic adenoviral candidates suitable for intravenous delivery and optimized for specific patient populations. Offerings include THEO-260 for platinum-resistant ovarian cancer, THEO-310 for multiple myeloma, proprietary adenovirus libraries for oncology, gene therapy and infectious diseases, and bioselection/screening systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theolytics company profile →
Somatex
HQ: Germany
Website
- Description: Provider of medical devices, located in Berlin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Somatex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Previse
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Previse
2.2 - Growth funds investing in similar companies to Previse
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Previse
4.2 - Public trading comparable groups for Previse
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →